Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Armata Pharmaceuticals, Inc. Director's Dealing 2005

Oct 4, 2005

34152_dirs_2005-10-04_65f78caa-63f6-4b7c-af22-dfa3f87e1071.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: TARGETED GENETICS CORP /WA/ (TGEN)
CIK: 0000921114
Period of Report: 2005-10-03

Reporting Person: Poston David J (Acting CFO)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 17000 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (right to buy) $2.25 2009-01-21 Common Stock (28000) Direct
Stock Option (right to buy) $8.56 2010-01-20 Common Stock (7500) Direct
Stock Option (right to buy) $6.66 2011-01-23 Common Stock (20000) Direct
Stock Option (right to buy) $5.95 2011-05-08 Common Stock (5000) Direct
Stock Option (right to buy) $2.57 2012-01-22 Common Stock (32000) Direct
Stock Option (right to buy) $0.76 2012-08-07 Common Stock (10000) Direct
Stock Option (right to buy) $1.31 2014-05-20 Common Stock (91000) Direct
Stock Option (right to buy) $0.91 2015-05-26 Common Stock (27000) Direct

Footnotes

F1: Such option is 100% vested and exercisable.

F2: Such option vests and is exercisable 6.25% quarterly, commencing April 22, 2002, with 100% vested and exercisable on April 22, 2006.

F3: Such option vests and is exercisable 6.25% quarterly, commencing November 7, 2002, with 100% vested and exercisable on November 7, 2006.

F4: Such option vests and is exercisable 6.25% quarterly, commencing August 20, 2004, with 100% vested and exercisable on August 20, 2008.

F5: Such option vests and is exercisable 6.25% quarterly, commencing August 26, 2005, with 100% vested and exercisable on August 26, 2009.